vs
DHT Holdings, Inc.（DHT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是DHT Holdings, Inc.的1.9倍（$207.3M vs $107.3M），DHT Holdings, Inc.净利率更高（41.7% vs -62.0%，领先103.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -24.5%）
DHT控股是一家独立的国际原油运输企业，持有并运营大型原油运输船队，主要服务全球油气行业，为头部石油生产商、炼油厂和大宗商品贸易商提供跨国际核心贸易航线的原油海运服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
DHT vs RARE — 直观对比
营收规模更大
RARE
是对方的1.9倍
$107.3M
营收增速更快
RARE
高出50.4%
-24.5%
净利率更高
DHT
高出103.8%
-62.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $107.3M | $207.3M |
| 净利润 | $44.8M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 44.2% | -54.7% |
| 净利率 | 41.7% | -62.0% |
| 营收同比 | -24.5% | 25.9% |
| 净利润同比 | 27.3% | 3.5% |
| 每股收益（稀释后） | $0.28 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DHTRARE
| Q4 25 | — | $207.3M | ||
| Q3 25 | $107.3M | $159.9M | ||
| Q2 25 | — | $166.5M | ||
| Q1 25 | — | $139.3M | ||
| Q4 24 | — | $164.6M | ||
| Q3 24 | $142.1M | $139.5M | ||
| Q2 24 | — | $147.0M | ||
| Q1 24 | — | $108.8M |
净利润DHTRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $44.8M | $-180.4M | ||
| Q2 25 | — | $-115.0M | ||
| Q1 25 | — | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $35.2M | $-133.5M | ||
| Q2 24 | — | $-131.6M | ||
| Q1 24 | — | $-170.7M |
营业利润率DHTRARE
| Q4 25 | — | -54.7% | ||
| Q3 25 | 44.2% | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 29.7% | -94.6% | ||
| Q2 24 | — | -79.1% | ||
| Q1 24 | — | -151.9% |
净利率DHTRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | 41.7% | -112.8% | ||
| Q2 25 | — | -69.0% | ||
| Q1 25 | — | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 24.8% | -95.7% | ||
| Q2 24 | — | -89.5% | ||
| Q1 24 | — | -156.8% |
每股收益（稀释后）DHTRARE
| Q4 25 | — | $-1.28 | ||
| Q3 25 | $0.28 | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | $0.22 | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $81.3M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $-80.0M |
| 总资产 | $1.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DHTRARE
| Q4 25 | — | $421.0M | ||
| Q3 25 | $81.3M | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | $73.8M | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
股东权益DHTRARE
| Q4 25 | — | $-80.0M | ||
| Q3 25 | $1.1B | $9.2M | ||
| Q2 25 | — | $151.3M | ||
| Q1 25 | — | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | $1.0B | $346.8M | ||
| Q2 24 | — | $432.4M | ||
| Q1 24 | — | $140.3M |
总资产DHTRARE
| Q4 25 | — | $1.5B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 1.36× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流DHTRARE
| Q4 25 | — | $-99.8M | ||
| Q3 25 | $60.9M | $-91.4M | ||
| Q2 25 | — | $-108.3M | ||
| Q1 25 | — | $-166.5M | ||
| Q4 24 | — | $-79.3M | ||
| Q3 24 | $80.1M | $-67.0M | ||
| Q2 24 | — | $-77.0M | ||
| Q1 24 | — | $-190.7M |
自由现金流DHTRARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率DHTRARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度DHTRARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
现金转化率DHTRARE
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.28× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DHT
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
